文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy.

作者信息

Shen Yao, Fan Nairui, Ma Shu-Xia, Cheng Xin, Yang Xuesong, Wang Guang

机构信息

International Joint Laboratory for Embryonic Development & Prenatal Medicine Division of Histology and Embryology School of Medicine Jinan University Guangzhou China.

Key Laboratory for Regenerative Medicine of the Ministry of Education Jinan University Guangzhou China.

出版信息

MedComm (2020). 2025 Apr 18;6(5):e70168. doi: 10.1002/mco2.70168. eCollection 2025 May.


DOI:10.1002/mco2.70168
PMID:40255918
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12006732/
Abstract

Dysbiosis refers to the disruption of the gut microbiota balance and is the pathological basis of various diseases. The main pathogenic mechanisms include impaired intestinal mucosal barrier function, inflammation activation, immune dysregulation, and metabolic abnormalities. These mechanisms involve dysfunctions in the gut-brain axis, gut-liver axis, and others to cause broader effects. Although the association between diseases caused by dysbiosis has been extensively studied, many questions remain regarding the specific pathogenic mechanisms and treatment strategies. This review begins by examining the causes of gut microbiota dysbiosis and summarizes the potential mechanisms of representative diseases caused by microbiota imbalance. It integrates clinical evidence to explore preventive and therapeutic strategies targeting gut microbiota dysregulation, emphasizing the importance of understanding gut microbiota dysbiosis. Finally, we summarized the development of artificial intelligence (AI) in the gut microbiota research and suggested that it will play a critical role in future studies on gut dysbiosis. The research combining multiomics technologies and AI will further uncover the complex mechanisms of gut microbiota dysbiosis. It will drive the development of personalized treatment strategies.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/f1b7a928512c/MCO2-6-e70168-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/1cba015bf86d/MCO2-6-e70168-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/b9691bc5a0ef/MCO2-6-e70168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/9041fdbae581/MCO2-6-e70168-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/c862489ab97d/MCO2-6-e70168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/f1b7a928512c/MCO2-6-e70168-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/1cba015bf86d/MCO2-6-e70168-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/b9691bc5a0ef/MCO2-6-e70168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/9041fdbae581/MCO2-6-e70168-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/c862489ab97d/MCO2-6-e70168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e878/12006732/f1b7a928512c/MCO2-6-e70168-g005.jpg

相似文献

[1]
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy.

MedComm (2020). 2025-4-18

[2]
Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.

J Hepatol. 2024-9

[3]
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.

Naunyn Schmiedebergs Arch Pharmacol. 2025-4-9

[4]
The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.

Microbiol Spectr. 2015-6

[5]
Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of .

Front Med (Lausanne). 2022-3-2

[6]
Gut dysbiosis contributes to the development of Budd-Chiari syndrome through immune imbalance.

mSystems. 2024-9-17

[7]
[Gut microbiota and immune crosstalk in metabolic disease].

Biol Aujourdhui. 2017

[8]
Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review.

Biomed Pharmacother. 2023-8

[9]
Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.

World J Gastroenterol. 2023-2-14

[10]
Relationship between Gut Microbiota, Gut Hyperpermeability and Obesity.

Curr Med Chem. 2021

引用本文的文献

[1]
Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non-alcoholic fatty liver disease progression.

World J Hepatol. 2025-8-27

[2]
Exploring the impact of artificial sweeteners on diabetes management and glycemic control.

Front Nutr. 2025-8-12

[3]
The Impact of Endocrine Disruptors on the Female Genital Tract Microbiome: A Narrative Review.

Life (Basel). 2025-7-24

[4]
Gut Microbiota in Exercise-Regulated Development, Progression, and Management of Type 2 Diabetes Mellitus: A Review of the Role and Mechanisms.

Med Sci Monit. 2025-8-6

[5]
Pathological mechanisms and treatment progression of Alzheimer's disease.

Eur J Med Res. 2025-7-14

[6]
Causal Relationship between Gut Microbiota and Endometrial Cancer: A Two-Sample Mendelian Randomization Study.

Int J Med Sci. 2025-6-23

[7]
Fermentation of Fruits and Vegetables: Bridging Traditional Wisdom and Modern Science for Food Preservation and Nutritional Value Improvements.

Foods. 2025-6-20

[8]
Gut microbiota and the "gut-liver-kidney axis" theory: from mechanisms to therapeutics.

Front Microbiol. 2025-6-19

[9]
Gut Microbiota and Cardiovascular Diseases: Unraveling the Role of Dysbiosis and Microbial Metabolites.

Int J Mol Sci. 2025-4-30

本文引用的文献

[1]
A gut commensal protozoan determines respiratory disease outcomes by shaping pulmonary immunity.

Cell. 2025-1-23

[2]
Using New Technologies to Analyze Gut Microbiota and Predict Cancer Risk.

Cells. 2024-12-1

[3]
Gut microbiota in health and disease: advances and future prospects.

MedComm (2020). 2024-11-20

[4]
Targeting gut microbiota as a therapeutic target in T2DM: A review of multi-target interactions of probiotics, prebiotics, postbiotics, and synbiotics with the intestinal barrier.

Pharmacol Res. 2024-12

[5]
AI in microbiome-related healthcare.

Microb Biotechnol. 2024-11

[6]
Gut-first Parkinson's disease is encoded by gut dysbiome.

Mol Neurodegener. 2024-10-24

[7]
Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression.

Sci Rep. 2024-9-27

[8]
Effects of probiotic treatment on patients and animals with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized control trials.

Front Cell Infect Microbiol. 2024

[9]
Fibroblast growth factor 21 improves insulin sensitivity by modulating the bile acid-gut microbiota axis in type Ⅱ diabetic mice.

Free Radic Biol Med. 2024-11-1

[10]
Probiotic-fermented traditional Chinese herbal medicine, a promising approach to maintaining the intestinal microecology.

J Ethnopharmacol. 2025-1-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索